Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of morphin-6-glucuronid for transdermal administration and preparation method and application of pharmaceutical composition

A glucuronide and transdermal drug delivery technology, which is applied to the transdermal drug composition of morphine-6-glucuronide and its preparation field, and can solve the problems of injection safety hazards, many adverse reactions, convulsions, etc.

Active Publication Date: 2020-06-30
YICHANG HUMANWELL PHARMA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patent CN107028968A discloses a small-capacity injection of morphine-6-glucuronide. The stabilizers in the prescription, such as edetate disodium and edetate calcium sodium, have many adverse reactions, such as kidney damage and electrocardiogram T wave changes. , histamine-like reaction, hypotension, dizziness, fever and other adverse reactions; especially for children, misuse of edetate disodium may lead to a severe decrease in blood calcium, convulsions and even death
Therefore, there are many safety hazards in the injection
Clinical use needs to be used under the guidance of a professional doctor, and the injection is often accompanied by injection pain, which is inconvenient for patients and poor compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of morphin-6-glucuronid for transdermal administration and preparation method and application of pharmaceutical composition
  • Pharmaceutical composition of morphin-6-glucuronid for transdermal administration and preparation method and application of pharmaceutical composition
  • Pharmaceutical composition of morphin-6-glucuronid for transdermal administration and preparation method and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Embodiment 1 Transdermal patch preparation of morphine-6-glucuronide hydrobromide

[0067] (1) Micronize 5 g of morphine-6-glucuronide hydrobromide, 2 g of povidone (PVP-S630) and 0.1 g of magnesium stearate, mix well to obtain a physical mixture, and add polyethylene glycol (Molecular weight 2000) 2.9g;

[0068] (2) Set the extrusion temperature of the twin-screw extruder to 120°C, start the screw after rising to the set temperature, add the physical mixture in step (1) to the extruder, heat-melt and extrude, It is extruded in the form of spherical particles to obtain amorphous particles, which are then micronized, and the particle size is controlled at about 100-150nm.

[0069] (3) Weigh 5 g of micronized amorphous particles prepared in step (2), 0.2 g of soybean lecithin, 0.03 g of cholesterol, 3 g of absolute ethanol, and 1.77 g of water;

[0070] (4) Dissolving soybean lecithin, cholesterol, and morphine-6-glucuronide hydrobromide microparticles in absolute ethan...

Embodiment 2

[0074] Embodiment 2 Transdermal patch preparation of morphine-6-glucuronide hydrochloride

[0075] (1) Micronize morphine-6-glucuronide hydrochloride 6g, povidone (PVP-S630) 1g, and talcum powder 0.2g, mix well to obtain a physical mixture, add polyethylene glycol (molecular weight 3000 )2.8g;

[0076] (2) Set the extrusion temperature of the twin-screw extruder to 100°C, start the screw after rising to the set temperature, add the physical mixture in step (1) to the extruder, heat-melt and extrude, It is extruded in the form of spherical particles to obtain amorphous particles, which are then micronized, and the particle size is controlled at about 150-200nm.

[0077] (3) Weigh 5 g of micronized amorphous particles prepared in step (2), 0.2 g of phosphatidylcholine, 0.08 g of cholesterol, 3 g of propylene glycol, and 1.72 g of water;

[0078] (4) Dissolving phosphatidylcholine, cholesterol, and morphine-6-glucuronide hydrochloride microparticles in propylene glycol, and hea...

Embodiment 3

[0082] Embodiment 3 Transdermal patch preparation of morphine-6-glucuronide sulfate

[0083] (1) morphine-6-glucuronide sulfate 7g and povidone (PVP-VA64) 1.5g magnesium stearate 0.1g are micronized, mix homogeneously, make physical mixture, add polyethylene glycol (molecular weight 4000) 1.4g;

[0084] (2) Set the extrusion temperature of the twin-screw extruder to 140°C, start the screw after rising to the set temperature, add the physical mixture in step (1) to the extruder, heat-melt and extrude, It is extruded in the form of spherical particles to obtain amorphous particles, which are then micronized, and the particle size is controlled at about 250-300nm.

[0085] (3) Weighing 7 g of micronized amorphous particles prepared in step (2), 2 g of dipalmitoylphosphatidylcholine, 0.3 g of cholesterol, 30 g of absolute ethanol, and 60.7 g of water;

[0086] (4) Dissolving dipalmitoylphosphatidylcholine, cholesterol, and morphine-6-glucuronide sulfate particles in absolute eth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a pharmaceutical composition for transdermal administration. The pharmaceutical composition comprises morphin-6-glucuronid or a pharmaceutically acceptable salt thereof, a polymer disperse carrier material, a hot melt protecting agent and an optional fluxing agent, wherein the pharmaceutical composition for transdermal administration is prepared by mixing the morphin-6-glucuronid or the pharmaceutically acceptable salt thereof, the polymer disperse carrier material, the hot melt protecting agent and the optional fluxing agent, and then carrying out hot melt extrusion and micronization to obtain particles of the morphin-6-glucuronid or the pharmaceutically acceptable salt thereof. In addition, the invention further provides a preparation method and application of thepharmaceutical composition. According to the pharmaceutical composition for transdermal administration, the morphin-6-glucuronid or the pharmaceutically acceptable salt thereof can be quickly absorbed to achieve the target of postoperative analgesia without affecting breathing, so that an adverse psychological effect to a patient caused by acupuncture of intramuscular injection or intravenous acupuncture is avoided; and meanwhile, the pharmaceutical composition can also be used for preventing and / or treating lumbar and cervical diseases of the patient.

Description

technical field [0001] The invention relates to pharmaceutical preparation technology, more specifically to a pharmaceutical composition for transdermal administration of morphine-6-glucuronide and its preparation method and application. Background technique [0002] Morphine-6-glucuronide [Morphine-6-glucuronide, referred to as M6G, as shown in formula (I), is the active metabolite of morphine in vivo. Morphine as an opioid is currently the most widely used narcotic analgesic for the treatment of moderate to severe pain, but studies have shown that it is not morphine itself that acts as an analgesic. Morphine is mainly combined with glucuronide in the liver and produces two metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G can bind to opioid receptors, and animal experiments show that its analgesic effect is stronger than that of morphine, and its adverse reactions are milder. M3G has a low affinity with opioid receptors and has no analgesic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61K9/70A61K9/127A61K47/28A61K47/10A61P19/08A61P17/02
CPCA61K31/706A61K9/7023A61K9/127A61K47/28A61K47/10A61P19/08A61P17/02
Inventor 李莉娥袁靖杨玉萍刘敏熊俊田峦鸢汪淼陈轶苗吕金良曲龙妹朱圣姬郭建锋李仕群杜文涛金芬
Owner YICHANG HUMANWELL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com